???global.info.a_carregar???
Carlos Fernandes (CF) graduated in Chemistry (2011) and finished his Master’s in chemistry in 2012 at the Faculty of Sciences University of Porto (FCUP). In 2014, CF was awarded for an international PhD fellowship by Foundation for Science and Technology (FCT). In 2018, CF was awarded with the European Doctorate title, and his PhD research was recognized by the prestigious Paul Ehrlich MedChem Network (http://www.pehrlichmedchem.eu/) as one of the best European PhD thesis in the Medicinal Chemistry field. Afterwards, CF was awarded with a Post-doctoral fellowship (2018) and hired by FCUP as principal researcher of a project funded by FCT (2019). In 2020, CF was hired as a doctorate researcher in a pharmaceutic/cosmetic company (MitoTAG), where he was responsible for the production of antioxidant compounds. In 2021, he was awarded with a 6-year contract in the IV call of Scientific Employment Stimulus funded by FCT (2021.04016.CEECIND). From 2020 up to now, CF has been lecturing BSc and MSc classes within the curricular units at the FCUP and during the years of 2022 and 2023, he was invited by FCUP as assistant professor. He is a member of the Researchers Committee of the Department of Chemistry and Biochemistry, FCUP (2023-now) and also an integrated member of the CIQUP-IMS (Chemistry Research Center-Institute of Molecular Sciences) research unit. He was a guest editor of a special issues of Molecules and actively collaborates as a referee in several journals in the Medicinal Chemistry and Nanomedicine areas. Carlos Fernandes's contributions to the research community and society are highlighted through his publications in peer-reviewed and open-access scientific journals, including 42 published papers (5 as the corresponding author) and 9 conference proceedings. Furthermore, he is co-author of 6-chapter books. Around 90% of papers were published in Q1 journals, receiving a total of 1148 citations, yielding an h-index of 17 (Source: ISI Web of knowledge). Several of his works have gathered scientific distinctions, such as the IACOBUS-papers Awards in 2019, 2021 and 2024 for his papers published in Molecules (2019), Eur J Med Chem (2021) and J Med Chem (2024).
Read full resume ↓
Identification

Personal identification

Full name
CARLOS EDUARDO VINHAS FERNANDES

Citation names

  • Fernandes, C.
  • Carlos Fernandes

Author identifiers

Ciência ID
C210-ADF3-94C4
ORCID iD
0000-0002-0102-0703
Researcher Id
AAC-7299-2019
Scopus Author Id
56346514700

Email addresses

  • Carlos.fernandes@fc.up.pt (Professional)

Knowledge fields

  • Engineering and Technology - Nano-technology
  • Engineering and Technology - Nano-technology - Nano-materials
  • Exact Sciences - Chemical Sciences
  • Exact Sciences - Chemical Sciences - Polymer Science
  • Medical and Health Sciences - Basic Medicine - Neurosciences

Languages

Language Speaking Reading Writing Listening Peer-review
English Intermediate (B1) Advanced (C1) Advanced (C1) Intermediate (B1)
Portuguese Advanced (C1) Advanced (C1) Advanced (C1) Advanced (C1)
French Beginner (A1) Intermediate (B1) Beginner (A1) Beginner (A1)
Projects

Contract

Designation Funders
2024 - Current Towards a personalized medicine for Amyotrophic Lateral Sclerosis: ROS-sensitive nanoparticles as carriers for combined drug delivery
2023.13291.PEX
Principal investigator
Ongoing
Outputs

Publications

Journal article
  1. Leitão, Miguel M.; Gonçalves, Ariana S.C.; Joana F. Moreira; Carlos Fernandes; Borges, Fernanda; Simões, Manuel; Borges, Anabela. "Unravelling the potential of natural chelating agents in the control of Staphylococcus aureus and Pseudomonas aeruginosa biofilms". European Journal of Medicinal Chemistry (2024): 117163. https://doi.org/10.1016/j.ejmech.2024.117163.
    Published • 10.1016/j.ejmech.2024.117163
  2. Soares, P.; Marques-Oliveira, R.; Alfenim, A.; Mena, D.; Fernandes, C.; Cagide, F.; Benfeito, S.; et al. "Targeting neuroinflammation and modulating iron dysregulation with innovative multitarget therapeutics for amyotrophic lateral sclerosis". European Journal of Clinical Investigation (2022): https://publons.com/wos-op/publon/54112269/.
  3. Martins, J.; Duarte, J.; Veloso, C.; Fernandes, C.; Videira, A.; Benfeito, S.; Santos, A.; et al. "Mitochondriotropic Antioxidant Based on Caffeic Acid (MC4) Protects H9c2 Cardiomyoblasts against the Cardiotoxicity of Doxorubicin". European Journal of Clinical Investigation (2021): https://publons.com/wos-op/publon/57402379/.
  4. Pinto, M. R. V.; Barreiro, S.; Silva, R.; Remiao, F.; Borges, F.; Fernandes, C.. "Rescuing a troubled tolcapone: nanomedicine on hepatotoxicity fight club". Toxicology Letters (2021): https://publons.com/wos-op/publon/54134797/.
    10.1016/S0378-4274(21)00632-9
  5. Veloso, C.; Duarte, J.; Martins, J.; Fernandes, C.; Videira, A.; Cagide, F.; Santos, A.; et al. "Mitochondria-targeted hydroxybenzoic acids prevent oxidative damage to normal human dermal fibroblasts". European Journal of Clinical Investigation (2021): https://publons.com/wos-op/publon/61726606/.
  6. Martins, E. Gil; Martins, D.; Silva, V.; Fernandes, C.; Remiao, F.; Borges, F.; Silva, R.. "Mechanisms underlying new psychoactive phenethylamines cytotoxicity". Toxicology Letters (2021): https://publons.com/wos-op/publon/58692382/.
  7. Fernandes, C.; Duarte, J.; Goncalves, B.; Veloso, C.; Martins, J.; Videira, A.; Soares, P.; et al. "Improving Nature: Targeting Hydroxybenzoic Acids to Mitochondria for Neuroprotection". European Journal of Clinical Investigation (2021): https://publons.com/wos-op/publon/61726602/.
  8. Pinto, M.; Fernandes, C.; Gil-Martins, E.; Silva, R.; Benfeito, S.; Cagide, F.; Borges, F.; Remiao, F.. "Bioavailability improvement of a monoamine oxidase-B inhibitor using PEGylated PCL-based nanoparticles". Toxicology Letters (2019): https://publons.com/wos-op/publon/31881651/.
  9. Fernandes, Carlos; Oliveira, Catarina; Benfeito, Sofia; Soares, Pedro; Garrido, Jorge; Borges, Fernanda. "Nanotechnology and Antioxidant Therapy: An Emerging Approach for Neurodegenerative Diseases". Current Medicinal Chemistry (2014): https://publons.com/wos-op/publon/11818907/.
    10.2174/0929867321666140915141836
Activities

Supervision

Thesis Title
Role 		Degree Subject (Type)
Institution / Organization
2024 - Current Towards precision medicine for Parkinson’s disease: ROS-sensitive nanoparticles as carriers for combined drugs delivery
Supervisor
Universidade do Porto Faculdade de Ciências, Portugal

Event organisation

Event name
Type of event (Role) 		Institution / Organization
2021/07/26 - 2021/07/28 Paul Ehrlich Virtual Meeting (2021/07/26 - 2021/07/28)
Meeting (Member of the Organising Committee)
 Universidade do Porto Faculdade de Ciências, Portugal
2021/05/07 - 2021/05/21 First webinar on Medicinal Chemistry – Designing Tomorrow’s Therapeutics, (2021/05/07 - 2021/05/21)
Conference (Member of the Organising Committee)
 Universidade do Porto Faculdade de Ciências, Portugal
2020/02/04 - 2020/02/20 II workshop meeting CIQUP (2020/02/20 - 2020/02/22)
Meeting (Member of the Organising Committee)
 Universidade do Porto Faculdade de Ciências, Portugal
2018/07/12 - 2018/07/14 VIII Meeting of the Paul Ehrlich Euro-PhD Network (2018/07/12 - 2018/07/14)
Congress (Member of the Organising Committee)
 Universidade do Porto Faculdade de Ciências, Portugal

Jury of academic degree

Topic
Role 		Candidate name (Type of degree)
Institution / Organization
2024/07 Desenvolvimento de nanoparticulas inteligentes para a entrega de farmacos para o tratamento da doença de Parkinson
Supervisor
 Isadora de Souza Silva (Other)
Universidade do Porto Faculdade de Ciências, Portugal

Evaluation committee

Activity description
Role 		Institution / Organization Funding entity
2024 - Current Member of the jury for the attribution of a research grant (Master’s Degree), enrolled in Scientific Research and Technological Development (SR&TD) Project with the reference UIDB/00081/2020-RG1
President
 Universidade do Porto Faculdade de Ciências, Portugal

Journal scientific committee

Journal title (ISSN) Publisher
2024/06 - Current Journal of Drug Delivery Science and Technology
2024 - Current ACS Applied Interface and Materials American Chemical Society